Answers are grounded in this paper and cite their sources.
Ventilator-associated pneumonia (VAP) is the most frequent infectious respiratory complication among intensive care unit (ICU) patients, yet its diagnosis remains challenging due to the absence of reliable gold-standard tools. This study investigated systemic transcriptomic and cytokine responses during VAP occurring between day 5–7 after ICU admission to identify potential blood-based biomarkers. We conducted a matched case–control retrospective analysis nested within a multicenter, prospective, non-interventional ICU cohort collected between December 2009 and June 2011. We selected mechanically ventilated patients who developed VAP, diagnosed according to the American Thoracic Society criteria, with episodes occurring between day 5 and day 7 after ICU admission. Fourteen VAP patients were matched with twenty-eight non-VAP controls based on demographics, severity scores, and admission characteristics. Whole blood RNA sequencing and multiplex plasma cytokine quantification were performed to characterize systemic immune profiles. The median duration of mechanical ventilation was 7 days, and ICU mortality reached 24%. No significant differentially expressed genes or cytokine level differences were identified when comparing VAP and non-VAP patients. As our cohort comprised sepsis and trauma patients, we performed similar analyses by subgroups and still observed no differences between VAP and non-VAP patients. In conclusion, despite several analyses, we were unable to detect systemic immune-related differences between VAP and non-VAP patients within this cohort. Consistent with previous reports, these findings support the hypothesis of a predominantly localized host response, which should be considered in the design of future VAP biomarker discovery studies.
No takes yet. Share an insight, caveat, or question.
Vernay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: